Recently, we have reported that EVA1A could inhibit EMT in HCC cells, by upregulating epithelial marker E-cadherin levels and downregulating mesenchymal markers N-cadherin and Vimen levels [10]. This evidence concerns the gene CDH2 and hepatocellular carcinoma.